Cannabis Science (CBIS) Applauds 'Historic Step Forward For Nation's Suffering Patients' As U.S. Senate Introduces A Medical Marijuana Bill To End Federal Prohibition

COLORADO SPRINGS, Colo., March 11, 2015 /PRNewswire/ -- Cannabis Science, Inc. (OTCQB: CBIS), a U.S. company specializing in the development of cannabis-based medicine, called today's introduction of a United States Senate bill that would end the federal ban on medical marijuana "a science-based blessing for patients across the United States" and a "common sense move that will contribute to significant new science-based research."

United States Senator Rand Paul CARERS Act Press Release: http://www.paul.senate.gov/?p=press_release&id=1310

The bi-partisan bill was introduced at a press conference by Senators Rand Paul (R-Ky.), Cory Booker (D-N.J.), and Kirsten Gillibrand (D-N.Y.). It would also downgrade medical marijuana's Drug Enforcement Agency classification from Schedule 1 to Schedule 2, allowing doctors to recommend its use to some patients like veterans in need, enable more research, and ease banking issues in providing services to the industry.  "The emotion of this tugs at your heart," said Sen. Paul.

"This is a medical treatment that has a medical effect," Sen. Gillibrand said of one cannabinoid medicine used to relieve a girl's seizures – hundreds each day. "And we should not have parents fearing that Child Services is going to be knocking on their door for trying to help their suffering children."

"This is history," said Raymond C. Dabney, Director, President & CEO and Co-Founder of Cannabis Science. "This is our best chance yet to get on with the work of relieving the suffering of children and veterans and patients across the United States. This legislation needs to see the light of day to encourage research, to bring investment into the field and to help beneficial medicines to get to the people who need them as quickly as possible."

The recorded press conference announcing the bill's introduction can be viewed here at this link:  https://www.youtube.com/watch?v=YTPi5lpXqOE  (It begins at 32:37)

Added Dabney, "I highly recommend watching the press conference video because you will see just how great the medical need is – you'll hear it directly from patients and parents, including a woman who suffered from nausea, insomnia and neuralgia, who said, 'Finally I have a medicine that answered my prayers.'"

The press conference also included patients who said they were able to get relief from medical cannabis while avoiding much stronger and addictive narcotics, a mother of a child seeking relief from severe epilepsy, and a military veteran who said that because of state law, he is a father, a husband, an employee "and a criminal in the eyes of the Commonwealth of Virginia."

In a joint statement, the sponsors said the legislation, called the Compassionate Access, Research Expansion and Respect States (CARERS) Act, would "allow patients, doctors and businesses in states that have already passed medical marijuana laws to participate in those programs without fear of federal prosecution."

Dabney said that if the bill becomes law, legitimate companies pursuing science-based cannabinoid treatments for disease would feel more free to pursue their research, as would independent scientists and physicians – who in many cases risk prosecution and loss of their livelihoods in order to help suffering patients.

"Some states are more progressive than others, and so patients and the industry must demand leadership from the top," Dabney said. "Public opinion and science are on our side."

In December, Congress approved an amendment that bars the Justice Department from using its funds to prevent states from implementing their medical marijuana laws — a significant victory for proponents of the practice. Medical marijuana has been approved to varying degrees in 23 states and D.C.

About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches.

Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Media Contacts:

VAN STONE PUBLICITY
Carrol Van Stone
[email protected] 
Tel: 304-671-0244

Cannabis Science, Inc.
Raymond C. Dabney
President & CEO, Co-Founder
[email protected]
Tel: 1.888.889.0888

Chad S. Johnson, Esq.
Director, COO & General Counsel
[email protected]
Tel: 1.888.889.0888

www.cannabisscience.com

SOURCE Cannabis Science, Inc.

Related Links

http://www.cannabisscience.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED